NASDAQ$WHWK
Whitehawk Therapeutics Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Aadi Bioscience reported financial results for the second quarter of 2023, featuring continued growth in FYARRO sales and pipeline expansion.
Aadi Bioscience announced its Q2 2023 financial results, highlighting a revenue of $6.2 million from FYARRO sales, reflecting an 80% increase year-over-year. The company is progressing with its PRECISION1 trial and expanding its pipeline to include programs in Endometrial Cancer and Neuroendocrine Tumors (NETs).
- FYARRO net product sales were $6.2 million in the second quarter, reflecting growth of approximately 6% over Q1 2023 and 80% over the prior year quarter.
- Interim analysis from PRECISION1 expected before the end of 2023.
- Planned initiation of Phase 2 combination trial in endometrial cancer in the fourth quarter of 2023.
- Planned initiation of Phase 2 study in neuroendocrine tumors (NETs) in the fourth quarter of 2023.
Headline financials
Revenue & EPS history
Aadi Bioscience · Revenue · Quarterly
$6.2M
Revenue by segment
Aadi Bioscience · $5.96M total across 1 segment · Q3 2023
- Product Sales, Net$5.96M—100.0%
Forward guidance
Aadi Bioscience anticipates continued progress with the PRECISION1 trial, expecting an interim analysis before the end of 2023. The company also plans to initiate Phase 2 trials in endometrial cancer and neuroendocrine tumors in the fourth quarter of 2023.
Tailwinds
- Interim analysis from PRECISION1 expected before the end of 2023.
- Enrollment continues to be well-balanced between the two arms.
- Planned initiation of Phase 2 combination trial in endometrial cancer in the fourth quarter of 2023.
- Planned initiation of Phase 2 study in neuroendocrine tumors (NETs) in the fourth quarter of 2023.
- Cash, cash equivalents and short-term investments as of June 30, 2023, were $134.9 million, which is expected to fund operations into 2025 based on current plans.
Headwinds
- Net loss for the three months ended June 30, 2023, was $18.0 million.
- Accumulated deficit(236,392)(203,198)
- Foreign exchange loss(3)
- Operating expenses increased.
- Loss from operations(19,545)
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+1.8%
Avg return
Earnings day
+2.9%
Avg return
5 days after
+4.1%
Avg return
30 days after
37%
11 / 30 earnings
Positive
+69.8%
Q1 2021
Best reaction
-18.7%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.3% | -5.5% | -0.7% | |
| Q3 2025 | -0.4% | -3.5% | +10.2% | |
| Q1 2025 | +4.9% | -4.0% | -9.5% | |
| Q4 2024 | -1.5% | +1.2% | +14.7% | |
| Q3 2024 | +5.5% | +5.5% | +21.6% | |
| Q2 2024 | -3.6% | -1.4% | +30.7% | |
| Q1 2024 | -10.9% | -11.4% | -17.5% | |
| Q4 2023 | +5.7% | +9.3% | +1.0% | |
| Q3 2023 | -6.6% | -5.4% | +2.9% | |
| Q2 2023 | -1.0% | +1.7% | -12.2% | |
| Q1 2023 | -18.7% | -17.2% | -4.7% | |
| Q4 2022 | -1.8% | -0.1% | +10.3% | |
| Q3 2022 | +5.1% | +1.2% | +1.7% | |
| Q2 2022 | -6.2% | -0.9% | -11.0% | |
| Q1 2022 | +21.2% | +30.1% | +21.5% | |
| Q4 2021 | +5.4% | +2.3% | -8.2% | |
| Q3 2021 | -16.6% | -8.9% | -13.4% | |
| Q2 2021 | +3.0% | +2.0% | -7.9% | |
| Q1 2021 | +69.8% | +74.1% | +69.0% | |
| Q4 2020 | +1.9% | +2.5% | -15.1% | |
| Q3 2020 | -2.2% | +21.7% | +60.9% | |
| Q2 2020 | +17.3% | +6.4% | -22.4% | |
| Q1 2020 | -0.2% | -1.3% | +82.3% | |
| Q4 2019 | -5.8% | -17.7% | -6.2% | |
| Q3 2019 | -2.6% | -3.6% | +0.9% | |
| Q2 2019 | -1.9% | -1.9% | +0.9% | |
| Q1 2019 | -0.9% | -1.9% | -5.7% | |
| Q4 2018 | +4.2% | +22.4% | -65.0% | |
| Q3 2018 | -1.4% | -11.7% | -2.3% | |
| Q2 2018 | -1.7% | +3.9% | -3.8% | |
| Q4 2011 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro